Genmab

	14/6 14:39 af Raun	Tror du får ret med 27xx..... Grunden til den store omsætning, tror jeg er grundet en del gevinsthjemtagning.... Når først US åbner, så kan gevinsthjemtagning ikke holde den tolbage længere ;-)
	14/6 14:31 af royal	Der er vild megen omsætning idag. Luk i 27xx :-)
	14/6 12:53 af Raun	;-)
	14/6 12:48 af Solsen	33 point i dag er vel også en slags modstand ;-)
	14/6 12:47 af Raun	Det kunne det i hvert fald godt ligne :-)
	14/6 12:45 af Rondo	var det omkring 2690 Genmab ville kunne mærke modstand... ?
	14/6 12:27 af E L	bit similar to BMS's HuMax-IL8, also below the radar, but recently a small new PhII in head and neck squamous cell carcinoma was started (link)
	14/6 12:25 af E L	lol. but you'll have plenty of time to refresh your memory before they will publish some results i imagine.
	14/6 11:59 af JørgenVarnæs	Funny with this Lundbeck stuff - its been going on for so long, I’ve forgotten everything about it…
	14/6 11:06 af E L	yes, agree, definitely positive
	14/6 10:53 af JørgenVarnæs	Exciting stuff EL. Primary completion is also imminent
	14/6 10:50 af gentogen	Thanks E L!! Great that we can count on you to watch out for everything. With very few updates on CT this looks as positive news.
	14/6 10:42 af E L	with a therapeutic effect on disease burden and function. The ability to offer a treatment that will change the course of the disease will offer a fundamental improvement compared to currently available symptomatic treatments. Orphan drug designation was granted by EMA in April 2021. The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated and what the body does to the drug in healthy subjects and patients with Parkinson’s diseaseNCT03611569
	14/6 10:42 af E L	Lu AF82422 is a monoclonal antibody (mAb) targeting the pathological form of the protein alpha-synuclein that is believed to play a pivotal role in the development and progression of e.g. multiple system atrophy (MSA) and Parkinson’s disease and other neurodegenerative disorders. By targeting pathological alpha-synuclein with an antibody that will inhibit aggregation and potentially clear pathological alpha-synuclein from the brain, the project aims to demonstrate delay of disease progression -
	14/6 10:41 af E L	Lundbeck watchers did not do their job, as it was also in the Q1 report ;-) (link)
	14/6 10:39 af E L	EMA Committee for Orphan Medicinal Products in April awarded Lu AF82422 Orphan drug designation (link) 2.1.4
	14/6 09:26 af Stroka	De gode takter forsætter. :-)
	14/6 08:34 af Stroka	God morgen. :-)
	14/6 08:26 af Helge Larsen/PI-redaktør	Aktier/tendens: Udsigt til grøn åbning med Vestas, Ørsted og Bavarian i fokus (link)
	14/6 07:01 af Helge Larsen/PI-redaktør	Mandagens aviser med Alm. Brand, Orphazyme og Pandora (link)
	14/6 06:56 af Helge Larsen/PI-redaktør	Asien: Tæt på rekordniveau - kinesiske markeder lukket (link)
	14/6 06:55 af Helge Larsen/PI-redaktør	God morgen. :-)
	14/6 06:53 af transalp	Go morgen... :)
	13/6 21:12 af Helge Larsen/PI-redaktør	"Ugens Vindere & Tabere: De amerikanske life science aktier, både health care og biotech, giver nu et krystalklart købssignal, efter flere måneders stilstand i biotekindeks. Det har også smittet meget positivt af på de danske life science aktier, blandt andet ALK-Abelló, Zealand Pharma, Genmab og Novo Nordisk". (link)

	13/6 21:10 af Bulder	The abstract they are talking about i this one (link)
	13/6 20:38 af Bulder	Hopefully at esmo in September.
	13/6 20:37 af Bulder	Which ofcourse means that the next data will be much more reliable.
	13/6 20:36 af Bulder	68 pts in the escalation phase, which we have seen data from now. In the expansion phase (running now) there will be 486 pts.
	13/6 20:16 af nohope	Early phase, smll numbers - well - how small ?
	13/6 19:16 af GeorgeBest	Fantastic data on subcutaneous single-agent #Epcoritamab with a manageable toxicity profile providing an overall response rate of 90% (55% CR rate) in a heavily pretreated group of patients (including CAR-T) with 90% refractory to CD20 mAbs in relapsed/refractory DLBCL. (link)
	13/6 08:33 af transalp	Go morgen, ja føj for en omgang. Livet er noget skrøbeligt noget.. go bedring til CE og go søndag.
	13/6 07:42 af Helge Larsen/PI-redaktør	God morgen oven en tragisk fodboldaften med et godt udfald for for Eriksen oven på hjertestoppet.
	13/6 07:06 af bibob	Frygtelig TV aften ( fodbold ) Resultatet er så lige gyldigt. Godt Christian klarede det.
	13/6 07:04 af bibob	God morgen. :-)
	12/6 16:04 af Stroka	ØU: Genmab - KøbAktuel kurs: 2649,00Genmab testede udbruddet fra intervallet 2130-2450 en enkelt gang, og det skete med succes. Derefter tog kursen et pænt hop, og nu er næste mål januar-toppen i 2738.
	12/6 12:22 af Bulder	Kyprolis and ixa are also possibilties.
	12/6 12:20 af Bulder	Agree with him. We’ll have to wait for Perseus and Auriga to conclude anything. But I wouldn’t be too optimistic.
	12/6 12:01 af Solsen	Rev has only a couple of years more before patent expiry.
	12/6 11:59 af E L	i saw a few MD's commenting on it yesterday, maybe that will interest you: (link)
	12/6 11:42 af Bulder	(link)
	12/6 11:05 af Bulder	But dara has to make a difference, or the combo will be too expensive.
	12/6 11:03 af Bulder	So there is still hope for dara as maintenance. 1: Longer follow up on Cassiopeia 2. And 2: The Perseus study is testing dara in combo with rev as maintenance.
	12/6 10:07 af Stroka	Tusinde tak E L. Min kommentar her: (link)
	12/6 09:48 af E L	small new Dara trial in Glioblastoma (brain cancer) (link)
	12/6 09:40 af Helge Larsen/PI-redaktør	Fantastisk. Thanks E L.
	12/6 09:22 af E L	Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment,
	12/6 09:22 af E L	EHA: Johnson & Johnson, nearing Sanofi showdown, bolsters Darzalex's myeloma lead with 'unprecedented' survival data (link)
	12/6 09:19 af E L	“These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.”
	12/6 09:18 af E L	Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed (link)
	12/6 09:18 af E L	goede morgen ;-)